FAVRILLE INC Earnings Conference Call (Q1 2008)  Today's Calls

Visit the TF Network Sites· Corporate IR Center · Institutional Investor Center · Individual Investor Center Download Plug-In Real Player 8 Basic Windows Media Player Other Conference Calls Other May 8 Calls Today's Calls

Call Details FAVRILLE INC Earnings Conference Call (Q1 2008) Thu, May 8, 2008, 5:00 pm Eastern Listen to the archived event audio About FAVRILLE INC (NasdaqGM:FVRL) Favrille, Inc., a biopharmaceutical company, engages in the development and commercialization of immunotherapies for the treatment of cancer and other diseases of the immune system. Its principal product candidate includes Specifid, a following rituxan induction therapy that is in phase III trial for the treatment of B-cell non-hodgkin’s lymphoma (NHL); a following rituxan induction therapy, which is in phase II trial for treating -naive or relapsed or refractory follicular B-cell NHL patients; a single therapeutic agent in relapsed or refractory NHL patients that is in phase II clinical trial; a following autologous stem cell transplantation therapy, which is in phase II clinical trial; a physician-sponsored phase II clinical trial product with maintenance rituxan for the treatment of indolent B-cell NHL; a phase II clinical trial product for patients with various forms of indolent B-cell NHL; and a phase II clinical trial product for patients, who have received prior therapy for their follicular B-cell NHL. The company’s other products include FAV-201, a t-cell receptor-based immunotherapy for previously treated patients that is in investigational new drug stage; and anti-CD20 antibodies, which are in preclinical development stage. Favrille was founded in 2000 and is based in San Diego, California. More Info: Quote | Profile | Reports | Research | Msgs | Insider | Financials | Analyst Ratings